GlassScriptPhysician profile
Elizabeth A Blanzy
NPI 1306580261
$9,767.92
in general payments reported to CMS, 2019-2025
60 companies · $3,936 in 2025
The $3,936 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $541 · 2023: $2,000 · 2024: $3,291 · 2025: $3,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,458 · Education: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,457.65 |
| Education | $769.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,599.18 | 2024-2025 | |
| Janssen Biotech, INC. | $1,436.75 | 2023-2025 | Tremfya, Darzalex, Tecvayli |
| Amgen INC. | $1,416.37 | 2023-2025 | Evenity, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $711.16 | 2024-2025 | |
| Lilly USA, LLC | $517.56 | 2023-2024 | Verzenio, Taltz, Retevmo |
| Genzyme Corporation | $367.72 | 2022-2025 | |
| Ucb, INC. | $268.35 | 2024-2025 | Bimzelx, Cimzia |
| Actelion Pharmaceuticals US, INC. | $262.24 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $216.58 | 2022-2025 | Saphnelo, Lynparza |
| Pfizer INC. | $174.82 | 2023-2025 | |
| Organon LLC | $173.62 | 2024-2025 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $165.42 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $146.49 | 2022-2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $129.14 | 2022-2024 | Fruzaqla, Iclusig, Cuvitru |
| Sobi, INC | $122.64 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $120.64 | 2022-2025 | Orencia |
| Eisai INC. | $120.00 | 2022-2024 | |
| Genentech USA, INC. | $119.43 | 2023-2025 | Actemra, Phesgo, Rozlytrek |
| Ani Pharmaceuticals, INC. | $115.09 | 2024-2025 | Purified Cortrophin Gel |
| Dendreon Pharmaceuticals LLC | $114.54 | 2023 | Provenge |
| Beigene USA, INC. | $109.93 | 2022-2023 | Brukinsa |
| Radius Health, INC. | $93.32 | 2024-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $89.50 | 2022-2025 | Strensiq |
| Seagen INC. | $81.36 | 2022-2023 | Tukysa, Padcev, Tivdak |
| Aurinia Pharma U.S., INC. | $80.60 | 2024-2025 | Lupkynis |
| Alvogen INC | $74.22 | 2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $63.47 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $55.00 | 2023-2025 | Benlysta, Zejula, Jemperli |
| Coherus Oncology, INC. | $49.17 | 2023 | |
| Fresenius Kabi USA, LLC | $49.05 | 2024-2025 | Idacio |
| Celgene Corporation | $48.73 | 2023 | Opdualag, Pomalyst, Reblozyl |
| Servier Pharmaceuticals LLC | $48.22 | 2022-2023 | |
| Taiho Oncology, INC. | $40.13 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $38.59 | 2023 | Libtayo |
| Daiichi Sankyo INC. | $36.29 | 2023 | Enhertu |
| Aveo Pharmaceuticals, INC. | $32.75 | 2022-2023 | Fotivda |
| Deciphera Pharmaceuticals INC. | $32.25 | 2023-2024 | Qinlock |
| Emd Serono, INC. | $29.60 | 2023 | Bavencio, Tepmetko |
| Emmaus Medical, INC. | $25.03 | 2023 | Endari |
| Octapharma USA, INC. | $23.12 | 2023 | Panzyga |
| Rigel Pharmaceuticals, INC. | $23.01 | 2023 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $21.89 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.73 | 2024 | |
| Cti Biopharma Corp. | $21.32 | 2023 | Vonjo |
| Kyowa Kirin, INC. | $21.31 | 2024 | Crysvita |
| Pharmaessentia USA Corporation | $21.03 | 2024 | Besremi |
| Alnylam Pharmaceuticals INC. | $20.81 | 2023 | Givlaari |
| Sun Pharmaceutical Industries INC. | $20.26 | 2022 | |
| Sumitomo Pharma America, INC. | $19.05 | 2023 | Orgovyx |
| Accord Healthcare, INC. | $18.48 | 2024 | |
| Morphosys, US INC. | $18.48 | 2022 | |
| Adc Therapeutics America, INC. | $17.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.51 | 2024 | Truxima |
| Apellis Pharmaceuticals, INC. | $16.62 | 2023 | Empaveli |
| Celltrion USA INC. | $16.38 | 2023 | Vegzelma |
| Hospira, INC. | $16.30 | 2024 | |
| Karyopharm Therapeutics INC. | $16.05 | 2023 | Xpovio |
| G1 Therapeutics, INC. | $14.54 | 2023 | Cosela |
| Tempus Ai, INC | $14.40 | 2024 | |
| Foundation Medicine, INC. | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Blanzy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.